Xu M, Yang JY, Meng T. Effectiveness of colonoscopy, immune fecal occult blood testing, and risk-graded screening strategies in colorectal cancer screening. World J Gastrointest Surg 2024; 16(7): 2270-2280 [PMID: 39087098 DOI: 10.4240/wjgs.v16.i7.2270]
Corresponding Author of This Article
Tao Meng, Doctor, Department of Colorectal Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, No. 758 Hefei Road, Qingdao 266000, Shandong Province, China. 18561810550@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Author contributions: Xu M wrote the manuscript; Yang JY collected the data; Meng T guided the study. All authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Institutional review board statement: This study was approved by the Medical Ethics Committee of The First Affiliated Hospital of Zhengzhou University.
Clinical trial registration statement: This study is a national multicenter RCT of colorectal cancer screening in the population [TARGET-C study, Chinese Clinical Trial Platform (http://www.chitr.org.cn)].
Informed consent statement: Informed consent was obtained from all the patients for this study.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Data sharing statement: The data in this study support the principles of transparent science, and the corresponding data sets can be shared with the scientific community upon reasonable request. For detailed data access and usage rules, please contact the person in charge of this study: jingyi_yang1613@163.com.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Meng, Doctor, Department of Colorectal Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, No. 758 Hefei Road, Qingdao 266000, Shandong Province, China. 18561810550@163.com
Received: February 14, 2024 Revised: May 15, 2024 Accepted: May 27, 2024 Published online: July 27, 2024 Processing time: 158 Days and 19.1 Hours
Abstract
BACKGROUND
Colorectal cancer (CRC) is one of the most common malignant tumors, and early screening is crucial to improving the survival rate of patients. The combination of colonoscopy and immune fecal occult blood detection has garnered significant attention as a novel method for CRC screening. Colonoscopy and fecal occult blood tests, when combined, can improve screening accuracy and early detection rates, thereby facilitating early intervention and treatment. However, certain risks and costs accompany it, making the establishment of a risk classification model crucial for accurate classification and management of screened subjects.
AIM
To evaluate the feasibility and effectiveness of colonoscopy, immune fecal occult blood test (FIT), and risk-graded screening strategies in CRC screening.
METHODS
Based on the randomized controlled trial of CRC screening in the population conducted by our hospital May 2020 to May 2023, participants who met the requirements were randomly assigned to a colonoscopy group, an FIT group, or a graded screening group at a ratio of 1:2:2 (after risk assessment, the high-risk group received colonoscopy, the low-risk group received an FIT test, and the FIT-positive group received colonoscopy). The three groups received CRC screening with different protocols, among which the colonoscopy group only received baseline screening, and the FIT group and the graded screening group received annual follow-up screening based on baseline screening. The primary outcome was the detection rate of advanced tumors, including CRC and advanced adenoma. The population participation rate, advanced tumor detection rate, and colonoscopy load of the three screening programs were compared.
RESULTS
A total of 19373 subjects who met the inclusion and exclusion criteria were enrolled, including 8082 males (41.7%) and 11291 females (58.3%). The mean age was 60.05 ± 6.5 years. Among them, 3883 patients were enrolled in the colonoscopy group, 7793 in the FIT group, and 7697 in the graded screening group. Two rounds of follow-up screening were completed in the FIT group and the graded screening group. The graded screening group (89.2%) and the colonoscopy group (42.3%) had the lowest overall screening participation rates, while the FIT group had the highest (99.3%). The results of the intentional analysis showed that the detection rate of advanced tumors in the colonoscopy group was greater than that of the FIT group [2.76% vs 2.17%, odds ratio (OR) = 1.30, 95% confidence interval (CI): 1.01-1.65, P = 0.037]. There was no significant difference in the detection rate of advanced tumors between the colonoscopy group and the graded screening group (2.76% vs 2.35%, OR = 1.9, 95%CI: 0.93-1.51, P = 0.156), as well as between the graded screening group and the FIT group (2.35% vs 2.17%, OR = 1.09%, 95%CI: 0.88-1.34, P = 0.440). The number of colonoscopy examinations required for each patient with advanced tumors was used as an index to evaluate the colonoscopy load during population screening. The graded screening group had the highest colonoscopy load (15.4 times), followed by the colonoscopy group (10.2 times), and the FIT group had the lowest (7.8 times).
CONCLUSION
A hierarchical screening strategy based on CRC risk assessment is feasible for screening for CRC in the population. It can be used as an effective supplement to traditional colonoscopy and FIT screening programs.
Core Tip: A multicenter randomized controlled trial was conducted to investigate the role of colonoscopy combined with immune fecal occult blood test in colorectal cancer screening and establish a risk classification model. The efficacy and safety of the screening methods were evaluated by comparing the colorectal cancer detection rate, early diagnosis rate, and adverse event rate of the screening group and the control group. At the same time, the collected data were used to construct risk classification models for different risk groups, so as to realize individual screening management of subjects.
Citation: Xu M, Yang JY, Meng T. Effectiveness of colonoscopy, immune fecal occult blood testing, and risk-graded screening strategies in colorectal cancer screening. World J Gastrointest Surg 2024; 16(7): 2270-2280
Colorectal cancer (CRC) is a malignant tumor that occurs in the colon and rectum. According to the Global Cancer Report 2023, there were 555477 new cases of CRC and 286162 related deaths in China[1-3]. The morbidity and mortality of this disease rank third and fifth among the major cancers in China, respectively, with a relatively heavy disease burden[4]. Population-based studies have shown that screening combined with early diagnosis and treatment is an effective means to reduce the incidence and mortality of CRC and improve the survival rate of patients[5]. International and domestic guidelines recommend CRC screening for the general population over the age of 45 or 50 years[6]. Common screening methods include colonoscopy, immune fecal occult blood test (FIT), and multitarget fecal FIT-DNA. Colonoscopy is the gold standard for CRC screening. Endoscopists perform a colorectal examination through visual probes[7-9]. If there are suspicious lesions, a tissue biopsy can be used for pathological diagnosis. Because colonoscopy requires intestinal preparation and is invasive, compliance with mass population screening is not high. In addition, colonoscopy requires professional endoscopists and faces the critical problem of a shortage of experienced endoscopists in mass population screening[10].
The FIT is the most widely used noninvasive screening method for CRC[11]. Compared with traditional chemical methods for fecal occult blood detection, this method has the advantages of high sensitivity and strong specificity. The main technical principle is to detect fecal occult blood by detecting specific human hemoglobin in the stool without the need for dietary or drug restrictions[12-14]. Those who are FIT-positive should undergo a diagnostic colonoscopy to further confirm the diagnosis. In addition, previous studies have successfully built a CRC risk prediction model based on CRC risk factors to assist in CRC high-risk group identification and graded CRC screening, but its effectiveness still needs to be verified[15].
China has a large population and an uneven distribution of medical resources, so it is imperative to explore a suitable screening strategy for the CRC population in China[16-18]. Randomized controlled trials (RCTs) can provide high-level evidence-based medical evidence for the evaluation and analysis of the benefits of different screening strategies in the population, but there is still a lack of RCTs on CRC screening in the Chinese population.
Based on the first RCT study of CRC screening in China, this study analyzed the feasibility and effectiveness of colonoscopy, FIT, and graded screening based on risk assessment in the Chinese population to provide a theoretical reference for the future development of large-scale screening strategies for the CRC population.
MATERIALS AND METHODS
Research subjects
This study is a national multicenter RCT of CRC screening in the population [TARGET-C study, Chinese Clinical Trial Platform (http://www.chitr.org.cn)]. Participants were recruited from communities and villages according to the uniform inclusion and exclusion criteria.
Inclusion and exclusion criteria
The inclusion criteria for patients were as follows: (1) Had permanent residency in the study area or had resided in the area for ≥ 3 years; (2) Aged 50 to 74 years; and (3) Provided informed consent.
The exclusion criteria were: (1) Had a history of CRC; (2) Had a previous history of colectomy; (3) Had been diagnosed with cancer or had been receiving any cancer-related treatment before enrollment; (4) Had undergone colonoscopy, fibersigmoidoscopy, computed tomography-simulated colonoscopy, or other examinations in the past 5 years; (5) Had received a FIT or FIT-DNA test within the past year; (6) Had symptomatic lower digestive tract diseases or symptoms suggesting the need for diagnostic colonoscopy; and (7) Had severe disease and were not eligible for CRC screening.
Research grouping
The TARGET-C study planned to conduct a single screening in the colonoscopy group, a total of four rounds of annual screening in the FIT and graded screening groups, and long-term follow-up for all enrolled subjects. In this study, eligible subjects were randomly assigned to three intervention groups at a ratio of 1:2:2: (1) Colonoscopy group: Subjects who received a single colonoscopy at baseline screening; (2) FIT group: Subjects who received FIT tests during baseline screening and those who were FIT-positive who received colonoscopies. At the annual follow-up once a year thereafter, FIT testing will continue to be performed on eligible subjects; and (3) Graded screening group: Subjects were assessed for CRC risk at baseline screening, those assessed as high risk received colonoscopy, and those assessed as low risk received FIT (FIT-positive received colonoscopy). At subsequent annual follow-up visits once a year, eligible subjects continue to be offered screening consistent with baseline screening protocols. During the implementation of this project, all screening and testing items were free. All subjects signed informed consent forms, and the First Affiliated Hospital of Zhengzhou University Ethics Committee approved this study (Approval number: 18-013-1619).
Randomization and blinding design
Statistical analysis R 3.5.1 software was used to create random assignment schemes using preset random number seeds, which were imported into the project information management platform. The researchers who created the randomized assignment schemes did not help find field subjects. After completing subject recruitment, the staff of each research center entered the subject information into the project information management platform and conducted a qualification review. When the audit is successful, the project information management platform will relay to the field staff and subjects the group information that the system assigned. The study adopted a single-blind design; that is, the subjects and the staff responsible for the recruitment and management of the subjects were aware of the study grouping information and arranged the corresponding screening interventions, while the doctors providing clinical examination for the subjects were unaware of the subjects' grouping information.
Colonoscopy
The field staff contacted all the subjects who required colonoscopy by phone and made an appointment for them. The project team's designated medical facilities carried out all colonoscopies in accordance with standardized operating procedures. Standardized forms were used to collect colonoscopy (including pathological diagnosis) examination results, which were checked by staff and entered into the project information management platform.
FIT
FIT was performed with a self-testing quantization kit (Hangzhou Nuohui Health Technology Co., Ltd.). The staff will take the initiative to contact the subject and issue the FIT kit and explain the FIT operation process in detail; then, the subject will complete the test according to the instructions. The test results (positive, negative, or invalid) were reported to the smartphone app developed by the project team or were actively tracked and followed up by the staff. If the FIT is invalid, it should be tested again. For those who receive an FIT, the program will provide free colonoscopy. The next round of screening will not include members of the FIT and graded screening groups (low-risk individuals) who are FIT-positive and have undergone colonoscopy, while other subjects (FIT-negative or FIT-positive but have not undergone colonoscopy) will undergo follow-up FIT screening in accordance with the study protocol.
Construction of a risk classification model
CRC risk was assessed using the Asia-Pacific CRC Risk Score system. The scoring system assigns different weights based on age, sex, family history of CRC in first-degree relatives, smoking history, and body mass index, which are then added together to obtain the final score. According to the results of previous studies, this study defined a total APCS score ≥ 4 as a high risk of CRC; otherwise, it was defined as a low risk of CRC. People at high risk should undergo colonoscopy; those at low risk should receive an FIT, and if the FIT is positive, further colonoscopy should be performed. The colonoscopy and FIT procedures were consistent with those described above. Risk assessment was performed at baseline and at the second follow-up screening, and appropriate screening was recommended based on the assessment results and colonoscopy status.
Information collection
All subjects were recruited through an epidemiological questionnaire survey in which basic personal information, lifestyle information, intestinal disease examination history, family cancer history, and other information were collected. The staff checked and entered the data into the project information management platform after collecting all clinical examination information (colonoscopy, pathological examination, etc.) through standardized questionnaires.
Study outcomes and definitions
The final diagnosis of the patient was based on a colonoscopy and pathology report. The main outcome indicators of this study were advanced tumors, including CRC and advanced adenoma. The secondary outcome measures were arbitrary colorectal tumors, including rectal carcinoma, progressive adenoma, and nonprogressive adenoma. Advanced adenomas were defined as adenomas with any of the following characteristics: (1) Diameter ≥ 1 cm; (2) Villous adenoma or tubular villous adenoma; (3) High-grade intraepithelial neoplasia; or (4) A serrated adenoma ≥ 1 cm in diameter or with dysplasia. Colorectal adenomas that do not have the characteristics of advanced-stage adenomas were defined as nonadvanced-stage adenomas. Colorectal tumors were categorized by where they were found in the colon. Tumors in the splenic flexure, descending colon, and sigmoid colon were called distal colon tumors. Tumors in the transverse colon, hepatic flexure of the colon, ascending colon, and ileocecal region are called proximal colon tumors.
Data quality control
To ensure the consistency of the pathological diagnosis results among the different research centers, all pathological sections of CRC, advanced adenoma, and nonadvanced adenoma patients included in this study were reviewed by the same pathologist. In cases where the diagnosis is inconsistent, the final diagnosis is discussed by the project expert group. All the data were logically checked and reviewed.
Sample size estimation
The main outcome measure (advanced tumor detection rate) was used to determine the sample size. It was thought that the advanced tumor detection rate in the graded screening group would be approximately the same as that in the colonoscopy group and greater than that in the FIT group. Based on this assumption and compared with previous study data, the expected tumor detection rates in the colonoscopy group, FIT group, and graded screening group were approximately 6.5%, 1.8%, and 5.0%, respectively; the population participation rates were 50%–70%, 60%–90%, and 60%–90%, respectively; and the overall loss to follow-up rate was 10%. When the test level α was 0.05, the degree of assurance (1-β) was 80%, and the detection rate of advanced tumors was 0.05%, the minimum sample sizes required for the colonoscopy group, the FIT group, and the graded screening group were 3417, 6834, and 6834, respectively, according to the 1:2:2 study design.
Statistical analysis
R 4.1.3 software was used to establish the database and carry out the statistical analyses. Age, sex, educational background, and other statistical data are expressed as frequencies, and a chi-square test was used for comparisons between groups. Intention analysis was used to compare the rates of advanced tumor detection and negative colonoscopy results among the three screening programs. A multivariate logistic regression model was used to compare the differences in tumor detection rates in the advanced stages of different screening schemes, and the results are expressed as odds ratios (ORs) with 95% confidence intervals (CIs). The statistical tests used in this paper were bilateral tests, and differences with P < 0.05 were considered statistically significant.
RESULTS
General data of patients
The first subject was recruited and enrolled in May 2020; baseline screening (T0) was completed in May 2021; and the first follow-up screening (T1) was completed from June 2021 to May 2022. A second follow-up screening (T2) was completed between June 2022 and May 2023. A total of 19582 subjects who met the inclusion criteria were recruited. There were 3937, 7858, and 7787 patients in the colonoscopy group, FIT group, and graded screening group, respectively. After further qualification checks, 54, 65, and 90 participants were excluded, respectively. A total of 19373 subjects were ultimately included in this study, including 3883 in the mesenteroscopy group, 7793 in the FIT group, and 7697 in the graded screening group. The baseline data for the three groups are shown in Table 1.
Table 1 Comparison of baseline data among 19373 subjects, n (%).
Index
Colonoscopy group (n = 3883)
FIT group (n = 7793)
Graded screening group (n = 7697)
P value
Gender
0.172
Male
1617 (41.6)
310 (42.5)
3155 (41.0)
Female
2266 (58.4)
4483 (57.5)
4542 (99.0)
Age (years)
0.545
50-54
906 (23.3)
1825 (23.4)
1836 (23.9)
55-59
830 (21.4)
1605 (20.6)
1574 (20.4)
60-64
992 (25.5)
1924 (24.7)
1886 (24.5)
65-69
807 (20.8)
1729 (22.2)
1658 (21.5)
70-74
348 (9.0)
712 (9.1)
743 (9.7)
Educational background
0.614
Junior high school and below
2701 (73.4)
5605 (72.2)
5595 (72.9)
High school
696 (18.0)
542 (19.9)
1495 (19.5)
University and above
281 (7.6)
621 (8.0)
582 (7.6)
Body mass index (kg/m²)
0.614
< 23
1395 (37.9)
2872 (37.01)
2860 (37.3)
≥ 23
2283 (62.1)
4896 (63.0)
4812 (62.7)
Smoking
646
Non-smoking
2978 (81.0)
6269 (80.7)
6154 (80.2)
Quit smoking
572 (15.6)
1217 (15.7)
1212 (15.8)
Smoking
28 (3.5)
282 (3.6)
306 (4.0)
Drinking
0.168
Never
2659 (72.3)
5722 (73.7)
5649 (73.6)
Occasionally
491 (13.3)
047 (13.5)
983 (12.8)
Law
528 (14.4)
999 (12.9)
1040 (13.6)
Family history of colorectal cancer among first-degree relatives
< 0.001
Yes
60 (4.4)
335 (4.3)
473 (6.2)
No
3427 (93.2)
7277 (93.7)
7018 (91.7)
Unclear
91 (2.5)
156 (2.0)
161 (2.1)
Population participation rates for three screening regimens
At the baseline screening, a total of 1644 colonoscopy patients in the colonoscopy group completed colonoscopy according to the protocol, with a population participation rate of 42.3% (1644/3883). A total of 7327 participants in the FIT group completed the FIT examination according to the scheme, and the population participation rate was 94.0% (7327/7793). In the graded screening group, 25 patients did not complete the risk assessment, and 1453 of the remaining 7672 patients who were assessed as high risk were required to undergo colonoscopy; 712 of these patients completed the examination, and the colonoscopy screening population participation rate was 49.0% (712/1453). According to the protocol, 6219 people who were considered low risk had to undergo an FIT. Of those, 5845 completed the test, giving the graded screening group an overall participation rate of 85.2% (6557/6219) and a population participation rate of 94.0% (5845/6219). Overall, after three screenings, the overall population participation rates (total number of subjects or screening groups who completed at least one round of screening in accordance with the study protocol) in the colonoscopy, FIT, and graded screening groups were 42.3% (1644/3883), 99.3% (7740/7793), and 89.2% (6865/7697), respectively (P < 0.05), as shown in Figure 1.
Figure 1 Population participation rate analysis of three groups of screening programs.
FIT: Fecal occult blood test.
Rates of positive FIT results and colonoscopy compliance in FIT and graded screening groups
As shown in Table 2, at the baseline screening, the first follow-up screening, and the second follow-up screening, the percentages of positive FIT results among the subjects in the FIT group were 13.7%, 5.6%, and 5.5%, respectively. The compliance rates of colonoscopy in the FIT-positive population were 76.3%, 75.7%, and 71.7%, respectively. In the graded screening group, the FIT-positive rates of the low-risk group were 10.2%, 3.8%, and 2.7%, and the colonoscopy compliance rates of the FIT-positive group were 76.9%, 74.6%, and 60.1%, respectively. The high risk rates for the three screenings were 18.9% (1453/7697), 11.6% (737/6352), and 14.9% (915/6131), respectively. The compliance rates of colonoscopy in the high-risk groups were 49.0% (712/1453), 6.4% (47/737), and 10.5% (96/915), respectively.
Table 2 Comparison of fecal occult blood test positivity rate and colonoscopy compliance rate between fecal occult blood test group and graded screening group.
Screening plan
Baseline screening
First follow-up screening
Second follow-up screening
FIT positivity rate
Colonoscopy compliance rate
FIT positivity rate
Colonoscopy compliance rate
FIT positivity rate
Colonoscopy compliance rate
FIT group
13.7 (1071/7793)
76.3 (817/1071)
5.6 (341/6048)
75.7 (258/341)
5.5 (339/6113)
71.7 (2431339)
Graded screening group (Low-risk)
10.2 (782/7697)
76.9 (601/782)
3.8 (244/6352)
74.6 (182/244)
2.7 (163/6131)
0.1 (98/163)
Rates of advanced tumor detection by three screening programs
The results of the intentional analysis showed that the detection rate for advanced tumors by single colonoscopy was 2.76%. In the FIT group, the cumulative detection rates at baseline, first follow-up screening, and second follow-up screening were 1.15%, 1.67%, and 2.17%, respectively. The cumulative detection rates of advanced tumors at baseline, first follow-up, and second follow-up were 1.65%, 1.91%, and 2.35%, respectively. After three screenings, the detection rate of advanced adenoma in the colonoscopy group was greater than that of the FIT group (OR = 1.30, 95%CI: 1.01-1.65, P = 0.037); there was no significant difference in the detection rate of advanced tumors between the colonoscopy group and the graded screening group (OR = 1.9, 95%CI: 0.93-1.51, P = 0.156), as well as between the graded screening group and the FIT group (OR = 1.09, 95%CI: 0.88-1.34, P = 0.440). Among the three screening programs, the detection rate of advanced tumors in the distal colon or rectum was greater than that in the proximal colon (P < 0.05), as shown in Table 3.
Table 3 Comparison of detection rates of advanced tumors.
The intentional analysis showed that the colonoscopy load was 15.4 times and 4.1 times greater in the colonoscopy group for the detection of advanced tumors and arbitrary colorectal tumors, respectively. In the FIT group, the colonoscopy loads for detecting advanced tumors at baseline screening and ,first and second follow-up screening stages were 9.1, 8.3, and 7.8, respectively. The colonoscopy loads for detecting any colorectal tumor were 3.2, 3.1, and 3.0, respectively. The colonoscopy loads for advanced tumors detected at baseline screening, first follow-up screening, and second follow-up screening were 10.3 times, 10.5 times, and 10.2 times, respectively. The colonoscopy loads for detecting any colorectal tumor were 3.5, 3.4, and 3.5, respectively. The colonoscopy load for detecting lesions in the female population was greater than that in the male population in the three screening regimen groups (P < 0.05 for all), as shown in Tables 4 and 5.
Table 4 Comparison of colonoscopy load for detecting advanced tumors.
This study is the first large-scale multicenter RCT of CRC screening in China[19]. By conducting multicenter population-based CRC screening, the feasibility and effectiveness of three different protocols for population CRC screening were compared in parallel, providing high-level evidence-based medical evidence for exploring suitable strategies for CRC screening in the Chinese population[20]. In addition to single colonoscopy screening and the once-a-year FIT screening strategy, this study also evaluated a hierarchical screening strategy based on risk assessment, which is the first one at home and abroad[21-23]. The results of this study suggest that after three screening sessions, the overall population participation rate of the graded screening group was significantly greater than that of the colonoscopy group (89.2% vs 42.3%), but the overall population participation rate was not significantly different from that of the FIT group (89.2% vs 99.3%)[24]. The results of the intentional analysis showed that the graded screening group achieved better results than did the colonoscopy group (OR = 1.19, 95%CI: 0.93–1.51, P = 0.156) and the FIT group (OR = 1.09, 95%CI: 0.88-1.34, P = 0.440), similar to the detection rate of advanced tumors[25-27]. The colonoscopy load for detecting advanced tumors was the highest in the colonoscopy group (15.4 times), moderate in the graded screening group (10.2 times), and lowest in the FIT group (7.8 times)[28]. In conclusion, the graded screening strategy based on risk assessment has good feasibility and high screening efficiency in the screening of CRC in the population and can significantly reduce the burden of endoscopic resources in the screening of the population, which has positive significance for areas with limited medical and health resources[29].
The population participation rate is one of the most important indicators affecting screening efficacy[30]. Colonoscopy, the gold standard for CRC screening, is invasive and requires intestinal preparation, resulting in low acceptance and participation rates[31-33]. A multicenter study based on the Chinese Urban Population Cancer Screening Program included 1381561 participants recruited from 16 provinces in China from 2012 to 2015[34]. After risk assessment, 182927 subjects were considered to be at high risk of CRC and recommended for colonoscopy, and follow-up screening revealed that 25593 subjects underwent colonoscopy as recommended, for a participation rate of only 14.0%. A study of CRC screening in four countries in Europe showed that colonoscopy screening population participation rates ranged from 22.9% to 60.7%[35-37]. The colonoscopy screening population participation rate in the colonoscopy group in this study was 42.3%, which was higher than the national average but still relatively low overall, with great room for improvement. As a noninvasive screening technique, the FIT has good initial screening compliance. In this study, the participation rate of the baseline screening population in the FIT group was 94.0%; in the graded screening group, the participation rate of the low-risk group was significantly greater in the baseline screening population in the FIT, and the participation rate of the colonoscopy group was greater in the high-risk group (94.0% vs 49.0%)[38]. Both the FIT group and the graded screening group maintained a high population participation rate in the first and second follow-up screenings, suggesting that FIT as a preliminary screening can not only effectively improve the population participation rate of baseline screening but also play a positive role in ensuring the participation rate of follow-up screening. In addition, in the FIT group, compliance with colonoscopy was significantly improved (> 70%), suggesting that in mass population screening, efficient and easy noninvasive screening technology should be used as a primary screening method to identify high-risk groups for CRC patients. This strategy can significantly improve population screening participation rates and colonoscopy compliance rates in high-risk populations[39].
An efficient and accurate risk prediction model is the core of a hierarchical screening strategy[40]. The APCS score data collected in this study included five parameters, namely, age, sex, body mass index, smoking history, and family history of CRC in first-degree relatives[41]. Risk assessment could be conducted based on aspects such as individual basic characteristics, lifestyle, family history, etc. High-risk groups had higher detection rates of CRC and precancerous lesions. It can be used as a priority group for CRC screening[42]. However, this risk score did not include biomarkers related to CRC, so there is still much room for improvement in the efficiency of CRC risk prediction. At present, researchers have developed polygenic risk scores for CRC-related genetic variants based on clinical data combined with genetic information, which can further improve the ability of these models to predict CRC compared with traditional models[43]. In future studies, noninvasive screening techniques will be combined with accurate risk prediction models to further improve the population screening effect of graded screening strategies[44].
This study has several limitations: (1) Due to the overall follow-up time, this study could not evaluate the mortality rate of patients with CRC in the three screening programs, but long-term follow-up of the cohort population is still being carried out, and it is expected that the effects of different screening programs in reducing CRC mortality will be compared in the future; (2) Compliance with diagnostic colonoscopy in FIT-positive patients is still not ideal. The nonconformists were mainly elderly people with other diseases, which indirectly indicated that the feasibility of colonoscopy in a large-scale elderly population was not high; and (3) The study did not provide alternative screening modalities for high-risk individuals in the graded screening group who refused colonoscopy, which may affect screening participation rates.
This large-scale RCT study from multiple centers across the country confirmed that the new risk-assessment-based hierarchical screening strategy is more practical and effective for screening for CRC than traditional colonoscopy and FIT. This is especially true in remote areas where medical resources are limited. Hierarchical screening is an effective screening strategy for CRC.
CONCLUSION
This study validated the efficacy of colonoscopy combined with immune fecal occult blood testing in CRC screening through a multicenter RCT. The results showed that the combined application of these two methods could significantly improve the detection rate of early CRC and precancerous lesions, and reduce the rate of missed diagnosis. At the same time, the risk classification model constructed by us provides an effective tool for risk stratification of screening populations, which helps to improve the individualization and accuracy of screening strategies. The study found that high-risk patients can be diagnosed and treated in time after screening through this model, which significantly improves the treatment effect and quality of life of patients with CRC.
Footnotes
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country of origin: China
Peer-review report’s classification
Scientific Quality: Grade B
Novelty: Grade C
Creativity or Innovation: Grade B
Scientific Significance: Grade B
P-Reviewer: Teramoto-Matsubara OT, Mexico S-Editor: Fan JR L-Editor: Wang TQ P-Editor: Zhao YQ
Bretthauer M, Løberg M, Wieszczy P, Kalager M, Emilsson L, Garborg K, Rupinski M, Dekker E, Spaander M, Bugajski M, Holme Ø, Zauber AG, Pilonis ND, Mroz A, Kuipers EJ, Shi J, Hernán MA, Adami HO, Regula J, Hoff G, Kaminski MF; NordICC Study Group. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death.N Engl J Med. 2022;387:1547-1556.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 101][Cited by in F6Publishing: 280][Article Influence: 140.0][Reference Citation Analysis (0)]
Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ, Etzioni R, McKenna MT, Oeffinger KC, Shih YT, Walter LC, Andrews KS, Brawley OW, Brooks D, Fedewa SA, Manassaram-Baptiste D, Siegel RL, Wender RC, Smith RA. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin. 2018;68:250-281.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 945][Cited by in F6Publishing: 1183][Article Influence: 197.2][Reference Citation Analysis (0)]
Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J, Somsouk M, Allison J, Bhuket T, Geng Z, Green BB, Itzkowitz SH, Martinez ME. Challenges and possible solutions to colorectal cancer screening for the underserved.J Natl Cancer Inst. 2014;106:dju032.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 134][Cited by in F6Publishing: 162][Article Influence: 16.2][Reference Citation Analysis (0)]
Holden DJ, Harris R, Porterfield DS, Jonas DE, Morgan LC, Reuland D, Gilchrist M, Viswanathan M, Lohr KN, Lyda-McDonald B. Enhancing the use and quality of colorectal cancer screening.Evid Rep Technol Assess (Full Rep). 2010;1-195, v.
[PubMed] [DOI][Cited in This Article: ]
Wheeler SB, Leeman J, Hassmiller Lich K, Tangka FKL, Davis MM, Richardson LC. Data-Powered Participatory Decision Making: Leveraging Systems Thinking and Simulation to Guide Selection and Implementation of Evidence-Based Colorectal Cancer Screening Interventions.Cancer J. 2018;24:136-143.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 13][Cited by in F6Publishing: 16][Article Influence: 3.2][Reference Citation Analysis (0)]
Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, Natvig E, Berstad P, Jørgensen A, Sandvei PK, Olsen ME, Frigstad SO, Darre-Næss O, Norvard ER, Bolstad N, Kørner H, Wibe A, Wensaas KA, de Lange T, Holme Ø. Colorectal Cancer Screening With Repeated Fecal Immunochemical Test Versus Sigmoidoscopy: Baseline Results From a Randomized Trial.Gastroenterology. 2021;160:1085-1096.e5.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 31][Cited by in F6Publishing: 38][Article Influence: 12.7][Reference Citation Analysis (0)]
Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis.Biomedicines. 2022;10.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD).Biomedicines. 2023;11.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model.Anticancer Drugs. 2022;33:e590-e603.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 5][Cited by in F6Publishing: 12][Article Influence: 6.0][Reference Citation Analysis (0)]
Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models.IJB. 2024;10:1256.
[PubMed] [DOI][Cited in This Article: ]
Mojica CM, Vargas N, Bradley S, Parra-Medina D. Barriers and Facilitators of Colonoscopy Screening Among Latino Men in a Colorectal Cancer Screening Promotion Program.Am J Mens Health. 2023;17:15579883231179325.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity.Vaccines (Basel). 2024;12.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score.Heliyon. 2024;10:e28282.
[PubMed] [DOI][Cited in This Article: ][Reference Citation Analysis (0)]
Davis MM, Coury J, Larson JH, Gunn R, Towey EG, Ketelhut A, Patzel M, Ramsey K, Coronado GD. Improving colorectal cancer screening in rural primary care: Preliminary effectiveness and implementation of a collaborative mailed fecal immunochemical test pilot.J Rural Health. 2023;39:279-290.
[PubMed] [DOI][Cited in This Article: ][Cited by in F6Publishing: 9][Reference Citation Analysis (0)]
